Elon Musk says there is a "massive cyber attack" underway against his platform X, formerly Twitter. He said on Monday local time that X gets "attacked every day, but this was done with a lot of ...

Elon Musk’s X was inaccessible on Monday morning for thousands of users, including many in the U.S. After about eight hours of outages, Musk posted that the platform is facing a “massive ...

A solution exists that could massively amplify government efforts by encouraging private parties to bring civil lawsuits against sanctions violators, borrowing a strategy called “qui tam” that ...

She regularly appears on CBS News 24/7 to discuss her reporting. Social media website X was down for many users on Monday, with its billionaire owner, Elon Musk, claiming the outage was the result ...

Hours after a series of outages Monday that left X unavailable to thousands of users, Elon Musk claimed that the social media platform was being targeted in a "massive cyberattack."Related video ...

After several hours of recurring outages Monday, Elon Musk took to X to explain why his social media network experienced widespread technical problems. “There was (still is) a massive ...

March 10 - Defensive tackle Sheldon Rankins is reuniting with the Houston Texans on a one-year, $7 million deal, ESPN reported Monday. Rankins, who turns 31 next month, previously played for the ...

Matthew Matasar, MD, discussed what the findings from the ELM-1 trial of odronextamab in diffuse large B-cell lymphoma mean for oncologists. Odronextamab (Ordspono) given as a monotherapy demonstrated ...

Chelsey Tam is a senior equity analyst for Morningstar.* She covers Chinese e-commerce and logistics stocks, such as Alibaba, JD.com, Pinduoduo, SF Holding, and ZTO Express. She is also ...

*Includes contributions from other candidate committees. NOTE: All the numbers on this page are for the 2019 - 2024 election cycle and based on Federal Election Commission data released electronically ...

A regulatory decision is expected by July 30, 2025. The US Food and Drug Administration (FDA) has accepted for review the resubmitted biologics license application for odronextamab to treat ...